QQ客服 官方微博 反馈留言

	Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
	Chi, Yihebali; Fang, Zhiwei; Hong, Xiaonan; Yao, Yang; Sun, Ping; Wang, Guowen; Du, Feng; Sun, Yongkun; Wu, Qiong; Qu, Guofan
刊名	CLINICAL CANCER RESEARCH
	2018
卷号	24期号:21
ISSN号	1078-0432
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3603553
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Chi, Yihebali,Fang, Zhiwei,Hong, Xiaonan,et al. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma[J]. CLINICAL CANCER RESEARCH,2018,24(21).
APA	Chi, Yihebali.,Fang, Zhiwei.,Hong, Xiaonan.,Yao, Yang.,Sun, Ping.,...&Cai, Jianqiang.(2018).Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.CLINICAL CANCER RESEARCH,24(21).
MLA	Chi, Yihebali,et al."Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma".CLINICAL CANCER RESEARCH 24.21(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。